Onco Actu du 27 avril 2016

	2. Etiologie
Kids' cancer risk might be tied to where mom was born [Reuters] The marked difference in risk for some cancers based on maternal origin means that lifestyle differences may be playing an important role, Heck said. “If there was no difference then genetics would be much more important,” she said.
	3.1 Tabac
Pentagon aims to curb tobacco use by military: memo [Reuters] A U.S. defense official, speaking on condition of anonymity, said that the U.S. military would raise the price to take into account taxes charged in local communities, which are not charged on-base.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
Industry, FDA Discuss Benefits of Data Sharing in Biomarker Development [RAPS] Because demonstrating the validity of a biomarker requires a considerable amount of data, the Critical Path Institute (C-Path) and other groups such as TransCelerate Biopharma have worked to develop ways to pool data from multiple sources.
	4.5 Dép., diag. & prono. - Colorectal
FDA Approves Blood-based Colorectal Cancer Screening Test [CANCER RESEARCH Catalyst] The FDA requires Epigenomics AG to conduct a postapproval study to investigate the long-term benefit of Epi proColon, and we look forward to learning whether or not it is able to increase the number of people who get screened for colorectal cancer.
	4.9 Dép., diag. & prono. - Sein
Well: Notifications About Dense Breasts Can Be Hard to Interpret [NY Times] “For many women, these notifications are not going to be easy to read” and might even be alarming, she said. “We’ve talked to some women who received these letters, and their reaction was ‘Oh my God, I have cancer.’ ”
	5. Traitements
Nanoparticles are all the rage in cancer treatment. But do they work? [STAT] Usually, people inject millions or billions of nanoparticles, but still the fact that less than 1 percent goes into the tumor speaks volumes about the concept of targeting.
	5.2 Pharma
How an open-science advocate aims to shake up pharma [STAT] Academics jump to industry all the time, but Bradner made his name with a move pharma almost never makes: When he discovered a potentially cancer-fighting molecule, he just gave it away.
	5.3 Traitements - FDA, EMA,...
Here Are Three Ways To Prevent Tragic Battles Between The FDA And Patients [Forbes] the day was filled with public testimony from some boys who had received the drug and their families. They said the medicine seemed to work. The discordance between the testimony and the data left some of the panelists distraught. It’s hard not to feel that something went wrong.
	5.3.4 Traitements - AMM (FDA, EMA)
Approved Drugs > Cabozantinib (CABOMETYX) [FDA] The approval was based on a randomized study in which patients with advanced renal cell carcinoma who had received prior anti-angiogenic therapy received either cabozantinib 60 mg orally once daily (N=330) or everolimus 10 mg orally once daily (N=328).
	5.4 Traitements - Economie
NICE recommends ovarian cancer treatments [NICE] NICE has published final guidance for five ovarian cancer drugs. Three of the drugs are not recommended, the other two are, in certain circumstances.
Drug Prices Keep Rising Despite Intense Criticism [NY Times] “It used to be the drug companies only took one price increase a year,” said Dr. Steve Miller, chief medical officer at Express Scripts. “Now what they’re doing is taking multiple price increases multiple times a year.”
States take aim at high drug prices [PWC] Since January 2015, 10 bills have been introduced in states such as California and Massachusetts requiring companies to disclose the cost to research, develop, produce and market many of their drugs.
	6. Lutte contre les cancers
Change Happens: The Incredibly Rapid Pace of Change In Cancer Care [Dr. Len's Blog] After spending a day listening to discussions of change in cancer care—led primarily by emerging data analytics and health information technology—I was struck how the cancer landscape might be shifting quickly in ways that many of us don’t understand, and in fact can’t fathom.
	6.1 Observation
Report warns of postcode lottery in NHS cancer care  [The Telegraph] Just 42 people out of 100 new cancer cases received chemotherapy in one area compared to 77 in the best performing region in 2014/15, the National Audit Office revealed.
	6.10 Politiques
Statement from American Society of Hematology President Charles S. Abrams, MD, on ASH Recommendations for the National Cancer Moonshot Initiative [ASH] Hematologists are pioneers in several fields that are revolutionizing cancer research, including immunotherapy, cell therapy, and genome sequencing – areas of study that are now showing great promise in treating solid tumors in addition to blood cancers.